What is PTD-DBM?
PTD-DBM is an experimental motif peptide investigated in Wnt-associated hair-follicle biology. The featured work included human tissue and cells alongside mouse experiments, rather than a controlled human hair-regrowth trial.
Biological role or research focus
Wnt signaling and hair-follicle models.
There was no controlled human treatment trial demonstrating hair restoration in the selected publication.
Role reference: Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. · 2017 ↗
Names you may encounter
Protein transduction domain–Dishevelled binding motif
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Experimental cell-penetrating motif peptide
- Research focus
- Wnt signaling and hair-follicle models
- Featured evidence
- Animal, cell, and human-tissue study
- Source check
- October 4, 2026
Quick answers
- Is PTD-DBM FDA approved?
- No. No FDA-approved drug contains PTD-DBM. Source ↗
- Is PTD-DBM safe?
- Experimental hair-regrowth peptide with no published human safety studies; it boosts growth signaling, and effects of that in people are unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is PTD-DBM banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| CXXC5–Dishevelled interference and hair regeneration (2017) | Animal, cell, and human-tissue study | Human scalp tissue and dermal-papilla cells, with mouse genetic and regeneration models. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal, cell, and human-tissue study · 2017
CXXC5–Dishevelled interference and hair regeneration
What did this publication test, and what did it find?
- Population / model
- Human scalp tissue and dermal-papilla cells, with mouse genetic and regeneration models.
- Study design
- Mechanistic tissue and cell experiments alongside animal experiments using genetic manipulation and peptide competition.
- Main finding
- The investigators reported changes in Wnt-associated signaling and hair-regrowth or follicle-generation measures in the experimental models.
- Limits & context
- There was no controlled human treatment trial demonstrating hair restoration in the selected publication.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming PTD-DBM as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD(2). ↗
Cells · 2023 Feb 9 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗
Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies. ↗
Cells · 2025 May 26 · Journal Article, Review
Read available full text ↗
Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment. ↗
Advanced healthcare materials · 2023 Jul · Journal Article, Research Support, Non-U.S. Gov't
The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. ↗
The Journal of experimental medicine · 2015 Jun 29 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗
Risks & interactions
Experimental hair-regrowth peptide with no published human safety studies; it boosts growth signaling, and effects of that in people are unknown.
No published human treatment or safety studies were found. Evidence comes from human scalp tissue, cell and mouse experiments that activate Wnt growth signaling; long-term effects of that in people are unknown.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Targeting CXXC5 by a competing peptide stimulates hair regrowth (2017) ↗
Safety & what remains unknown
Changing growth-related signaling requires clinical safety evidence. Laboratory and mouse observations cannot establish safe human hair treatment.
Evidence boundaries
There was no controlled human treatment trial demonstrating hair restoration in the selected publication.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This profile covers experimental hair and wound-associated follicle research. Human tissue in a laboratory study does not establish a patient treatment result.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Biology & proposed mechanism
The strategy interferes with the CXXC5–Dishevelled interaction in a Wnt-signaling context. Model pathway responses require separate clinical confirmation.
Questions worth asking
- Does inclusion of human scalp tissue make this a clinical trial?
- What material, population, and route were actually studied?
- There was no controlled human treatment trial demonstrating hair restoration in the selected publication.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does inclusion of human scalp tissue make this a clinical trial?
No. Studying tissue outside the body is different from treating participants and measuring clinical outcomes.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
